登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、对外投资进展情况 广东弘景光电科技股份有限公司（以下简称"公司"）与上海慕华金誉股权投资管理合伙企业（有限合 伙）及其他有限合伙人签署了《共青城慕智合创创业投资合伙企业（有限合伙）合伙协议》，共同投资 设立共青城慕智合创创业投资合伙企业（有限合伙）（以下简称"合伙企业"）。合伙企业的目标认缴规 模为人民币29,000万元，其中首关规模为人民币7,250万元，公司作为有限合伙人以自有资金出资300万 元认购合伙企业的基金份额。 近日，公司收到基金管理人上海慕华金誉股权投资管理合伙企业（有限合伙）的通知，根据《私募投资 基金监督管理暂行办法》等法律法规的要求，合伙企业已在中国证券投资基金业协会完成备案手续，并 取得《私募投资基金备案证明》，具体信息如下： 备案编码：SBSB21 基金名称：共青城慕智合创创业投资合伙企业（有限合伙） 管理人名称：上海慕华金誉股权投资管理合伙企业（有限合伙） 托管人名称：华夏银行股份有限公司 备案日期：2026年2月24日 具体内容详 ...

证券代码：301479 证券简称：弘景光电 公告编号：2026-002 广东弘景光电科技股份有限公司 关于与专业投资机构共同投资设立合伙企业的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、对外投资进展情况 广东弘景光电科技股份有限公司（以下简称"公司"）与上海慕华金誉股权投 资管理合伙企业（有限合伙）及其他有限合伙人签署了《共青城慕智合创创业投资 合伙企业（有限合伙）合伙协议》，共同投资设立共青城慕智合创创业投资合伙企 业（有限合伙）（以下简称"合伙企业"）。合伙企业的目标认缴规模为人民币 29,000 万元，其中首关规模为人民币 7,250 万元，公司作为有限合伙人以自有资金出资 300 万元认购合伙企业的基金份额。 具体内容详见公司于 2026 年 2 月 5 日披露的《关于与专业投资机构共同投资设 立合伙企业的公告》（公告编号：2026-001）。 近日，公司收到基金管理人上海慕华金誉股权投资管理合伙企业（有限合伙） 的通知，根据《私募投资基金监督管理暂行办法》等法律法规的要求，合伙企业已 在中国证券投资基金业协会完成备案手续，并取得《私 ...

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - The company announced a partnership to establish a venture capital fund focused on artificial intelligence and related industries, aiming for capital appreciation and investment returns [2][3] Group 1: Investment Details - The partnership involves 弘景光电 and Shanghai Muhua Jinyu Equity Investment Management Partnership, with a target subscription scale of RMB 29 million and an initial closing scale of RMB 7.25 million [2] - 弘景光电 plans to invest RMB 3 million as a limited partner in the fund, alongside other partners including 中山大洋电机股份有限公司 and 智元创新（上海）科技股份有限公司 [2] - The fund's investment period is set for seven years, with the first four years designated for investment activities [2] Group 2: Strategic Objectives - The investment aims to leverage the expertise of professional investment institutions in industry research and value discovery to focus on high-potential companies [3] - The initiative is expected to foster collaboration with companies in the artificial intelligence and embodied intelligence sectors, enhancing the company's competitive edge and sustainable development capabilities [3]

Core Viewpoint - The company, Hongjing Optoelectronics (301479.SZ), is focusing on the application of optical lenses and camera modules in various fields such as artificial intelligence hardware, robotics, industrial inspection, and healthcare, aiming to seize opportunities and cultivate new growth points [1] Group 1: Product Focus - The company's products include optical lenses and camera modules [1] - The company is actively monitoring the applications of its products in AI hardware, robotics, industrial inspection, and healthcare [1] Group 2: Healthcare Applications - In the healthcare sector, the company can provide customized solutions for lenses and modules to its clients [1] - Currently, the revenue from related healthcare business constitutes a low proportion of the company's total revenue, having a minimal impact on overall operational performance [1]

Group 1 - The company, Hongjing Optoelectronics, is actively exploring applications of optical lenses and camera modules in fields such as artificial intelligence hardware, robotics, industrial inspection, and healthcare [1] - The company provides customized solutions for lenses and modules in the medical sector, although the revenue from this segment currently constitutes a low proportion of the overall revenue, having a limited impact on the company's overall performance [1]

Core Viewpoint - Hongjing Optoelectronics (301479.SZ) aims to deepen industrial synergy and implement strategic layout by leveraging the capabilities and resource advantages of professional institutions, while simultaneously engaging in equity investments in emerging industries to promote effective integration of industry and capital [1] Group 1 - On February 3, 2026, Hongjing Optoelectronics signed a partnership agreement with Shanghai Muhua Jinyu Equity Investment Management Partnership (Limited Partnership) and other limited partners to establish the Qiongqing City Muzhi Hechuang Venture Capital Partnership (Limited Partnership) [1] - The target subscription scale of the partnership is set at RMB 290 million, with an initial closing scale of RMB 72.5 million [1] - The company plans to invest RMB 3 million of its own funds to subscribe for fund shares in the partnership [1] Group 2 - The investment strategy will focus primarily on direct or indirect equity investments, quasi-equity investments, or activities related to investments in companies within the artificial intelligence and embodied intelligence sectors [1]

Core Viewpoint - The company has signed a partnership agreement to jointly invest in a new venture capital firm, aiming to raise a total of RMB 290 million, with an initial closing of RMB 72.5 million [1] Group 1 - The company will participate as a limited partner, contributing RMB 3 million to the fund [1] - The partnership involves Shanghai Muhua Jinyu Equity Investment Management Partnership and other limited partners [1] - The venture capital firm is named "Muzhi Hechuang" [1]

| 3.内部审计部门和审计委员会的人员构成是否合规（如适 | √ | | --- | --- | | 用） | | | 4.审计委员会是否至少每季度召开一次会议，审议内部审计 | √ | | 部门提交的工作计划和报告等（如适用） | | | 5.审计委员会是否至少每季度向董事会报告一次内部审计工 | √ | | 作进度、质量及发现的重大问题等（如适用） | | | 6.内部审计部门是否至少每季度向审计委员会报告一次内部 | | | 审计工作计划的执行情况以及内部审计工作中发现的问题等 | √ | | （如适用） | | | 7.内部审计部门是否至少每季度对募集资金的存放与使用情 | √ | | 况进行一次审计（如适用） | | | 8.内部审计部门是否在每个会计年度结束前二个月内向审计 | √ | | 委员会提交次一年度内部审计工作计划（如适用） | | | 9.内部审计部门是否在每个会计年度结束后二个月内向审计 | √ | | 委员会提交年度内部审计工作报告（如适用） | | | 10.内部审计部门是否至少每年向审计委员会提交一次内部 | √ | | 控制评价报告（如适用） | | | 11.从事风险投资、 ...

证券代码：301479 证券简称：弘景光电 公告编号：2026-001 广东弘景光电科技股份有限公司 关于与专业投资机构共同投资设立合伙企业的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、对外投资概述 为深化产业协同、落实战略布局，借助专业机构的能力与资源优势，在立足主 业的同时进行新兴产业股权投资，推进产业与资本的有效融合，广东弘景光电科技 股份有限公司（以下简称"公司"）于 2026 年 2 月 3 日与上海慕华金誉股权投资管 理合伙企业（有限合伙）（以下简称"慕华金誉""普通合伙人"）及其他有限合 伙人签署了《共青城慕智合创创业投资合伙企业（有限合伙）合伙协议》（以下简 称"合伙协议""本协议"），拟共同投资设立共青城慕智合创创业投资合伙企业 （有限合伙）（以下简称"慕智合创""合伙企业"）。合伙企业的目标认缴规模 为人民币 29,000 万元，其中首关规模为人民币 7,250 万元，公司作为有限合伙人拟 以自有资金出资 300 万元认购合伙企业的基金份额。 公司控股股东、实际控制人、持股 5%以上的股东、董事、高级管理人员未参与 认购慕智合 ...